Kapur Ankur, Hurst Dow P, Fleischer Daniel, Whitnell Rob, Thakur Ganesh A, Makriyannis Alexandros, Reggio Patricia H, Abood Mary E
California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA.
Mol Pharmacol. 2007 Jun;71(6):1512-24. doi: 10.1124/mol.107.034645. Epub 2007 Mar 23.
Ligands of structurally diverse natures are able to bind at the CB(1) cannabinoid receptor, suggesting the existence of multiple binding sites on the receptor. Modeling studies have implicated Ser2.60(173) and Ser7.39(383) as possible interaction site(s) for CB(1) agonists. To test the importance of these residues for receptor recognition, recombinant human CB(1) receptors, stably expressed in human embryonic kidney 293 cells, were used to investigate the consequences of mutating Ser2.60 (to S2.60A) or Ser7.39 (to S7.39A) in radioligand binding and guanosine 5'-3-O-(thio)triphosphate functional assays. The S7.39A mutant resulted in a total ablation of (3)H-3-[2-hydroxyl-4-(1,1-dimethylheptyl)phenyl]-4-[3-hydroxylpropyl] cyclohexan-1-ol (CP55,940) high-affinity binding. However, (3)H-(+)-2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]-pyrrolo[1,2,3-de]-1,4-benzoxazin-6-ylmethanone (WIN55,212-2) binding properties at S7.39A were comparable with those of the wild-type (WT) receptor. The binding affinity of (-)-11beta-hydroxy-3-(1',1'-dimethylheptyl)hexahydrocannabinol (AM4056) and (-)-11-hydroxydimethylheptyl-Delta(8)-tetrahydrocannabinol (HU210) were drastically reduced (50- to 100-fold) at the S7.39A mutant. Likewise, the EC(50) for HU210 and AM4056-mediated activation of the S7.39A receptor was increased by >200-fold. In contrast, the binding affinity and potency of WIN55,212-2, CP55,940, HU210, and AM4056 were unaltered at the S2.60A mutant compared with WT human CB(1) receptors. These results clearly suggest that Ser7.39, but not Ser2.60, plays a crucial role in mediating ligand specific interactions for CP55,940, HU210, and AM4056 at the human CB(1) receptor. Our modeling studies predict that Ser7.39 in a g-chi1 conformation may induce a helix bend in TMH7 that provides docking space for CP55,940 binding; the S7.39A mutation may alter this binding space, precluding CP55,940 binding.
结构性质多样的配体能够结合大麻素CB(1)受体,这表明该受体上存在多个结合位点。建模研究表明,Ser2.60(173)和Ser7.39(383)可能是CB(1)激动剂的相互作用位点。为了测试这些残基对受体识别的重要性,利用在人胚肾293细胞中稳定表达的重组人CB(1)受体,研究了在放射性配体结合和鸟苷5'-3-O-(硫代)三磷酸功能测定中Ser2.60(突变为S2.60A)或Ser7.39(突变为S7.39A)的影响。S7.39A突变体导致(3)H-3-[2-羟基-4-(1,1-二甲基庚基)苯基]-4-[3-羟基丙基]环己醇(CP55,940)的高亲和力结合完全消失。然而,(3)H-(+)-2,3-二氢-5-甲基-3-[(4-吗啉基)甲基]-吡咯并[1,2,3-de]-1,4-苯并恶嗪-6-基甲酮(WIN55,212-2)在S7.39A处的结合特性与野生型(WT)受体相当。(-)-11β-羟基-3-(1',1'-二甲基庚基)六氢大麻酚(AM4056)和(-)-11-羟基二甲基庚基-Δ(8)-四氢大麻酚(HU210)在S7.39A突变体处的结合亲和力大幅降低(50至100倍)。同样,HU210和AM4056介导的S7.39A受体激活的EC(50)增加了200倍以上。相比之下,与野生型人CB(1)受体相比,WIN55,212-2、CP55,940、HU210和AM4056在S2.60A突变体处的结合亲和力和效力未发生改变。这些结果清楚地表明,Ser7.39而非Ser2.60在介导人CB(1)受体上CP55,940、HU210和AM4056的配体特异性相互作用中起关键作用。我们的建模研究预测,处于g-chi1构象的Ser7.39可能会在跨膜螺旋7(TMH7)中诱导螺旋弯曲,从而为CP55,940的结合提供对接空间;S7.39A突变可能会改变这种结合空间从而阻止CP55,940的结合。